We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Effect of Body-mass Index (BMI) on Median Effective Dose of Intrathecal Hyperbaric Bupivacaine

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01291186
First Posted: February 8, 2011
Last Update Posted: August 3, 2011
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Seoul Medical Center
  Purpose
The effect of Body-mass index (BMI) on requirements of local anesthetics used in spinal anesthesia has not been well established. The investigators tried to quantify the effect of BMI on spinal anesthesia by comparing the median effective dose of intrathecal bupivacaine between two different BMI groups.

Condition Intervention
Arthroplasty, Knee Drug: BPV6NO Drug: BPV7NO Drug: BPV8NO Drug: BPV9NO Drug: BPV10NO Drug: BPV11NO Drug: BPV6O Drug: BPV7O Drug: BPV8O Drug: BPV9O Drug: BPV10O Drug: BPV11O

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Official Title: The Effect of BMI on Median Effective Dose (ED50) of Intrathecal Hyperbaric Bupivacaine for Total Knee Replacement Arthroplasty

Resource links provided by NLM:


Further study details as provided by Seoul Medical Center:

Primary Outcome Measures:
  • success of spinal anesthesia [ Time Frame: every ten minutes during the surgery ]
    a bilateral T12 sensory level to pinprick within 10 min of the intrathecal drug administration with no additional epidural anesthetics required during the surgery


Secondary Outcome Measures:
  • time to first request for supplemental analgesia [ Time Frame: every ten minutes during and after surgery ]
    for failure cases: it is the time of failure for success cases : it is the time of first postoperative pain


Enrollment: 108
Study Start Date: January 2010
Study Completion Date: December 2010
Primary Completion Date: December 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: BPV6NO Drug: BPV6NO
intrathecal bupivacaine 6 mg for BMI less than 27.5 kg/m2
Other Names:
  • bupivacaine
  • epinephrine
Experimental: BPV7NO Drug: BPV7NO
intrathecal bupivacaine 7 mg for BMI less than 27.5 kg/m2
Other Names:
  • bupivacaine
  • epinephrine
Experimental: BPV8NO Drug: BPV8NO
intrathecal bupivacaine 8 mg for BMI less than 27.5 kg/m2
Other Names:
  • bupivacaine
  • epinephrine
Experimental: BPV9NO Drug: BPV9NO
intrathecal bupivacaine 9 mg for BMI less than 27.5 kg/m2
Other Names:
  • bupivacaine
  • epinephrine
Experimental: BPV10NO Drug: BPV10NO
intrathecal bupivacaine 10 mg for BMI less than 27.5 kg/m2
Other Names:
  • bupivacaine
  • epinephrine
Experimental: BPV11NO Drug: BPV11NO
intrathecal bupivacaine 11 mg for BMI less than 27.5 kg/m2
Other Names:
  • bupivacaine
  • epinephrine
Active Comparator: BPV6O Drug: BPV6O
intrathecal bupivacaine 6 mg for BMI over 27.5 kg/m2
Other Names:
  • bupivacaine
  • epinephrine
Active Comparator: BPV7O Drug: BPV7O
intrathecal bupivacaine 7 mg for BMI over 27.5 kg/m2
Other Names:
  • bupivacaine
  • epinephrine
Active Comparator: BPV8O Drug: BPV8O
intrathecal bupivacaine 8 mg for BMI over 27.5 kg/m2
Other Names:
  • bupivacaine
  • epinephrine
Active Comparator: BPV9O Drug: BPV9O
intrathecal bupivacaine 9 mg for BMI over 27.5 kg/m2
Other Names:
  • bupivacaine
  • epinephrine
Active Comparator: BPV10O Drug: BPV10O
intrathecal bupivacaine 10 mg for BMI over 27.5 kg/m2
Other Names:
  • bupivacaine
  • epinephrine
Active Comparator: BPV11O Drug: BPV11O
intrathecal bupivacaine 11 mg for BMI over 27.5 kg/m2
Other Names:
  • bupivacaine
  • epinephrine

Detailed Description:
The effect of BMI on requirements of local anesthetics used in spinal anesthesia has not been well established. The investigators tried to quantify the effect of BMI on spinal anesthesia by comparing the median effective dose (ED50)of intrathecal bupivacaine between two different BMI groups. The investigators determined the ED50 and ED 95 of intrathecal hyperbaric bupivacaine of subjects with BMI below 27.5 kg/m2, and subjects with BMI over 27.5 kg/m2, respectively. By comparing the difference of ED50 and ED95 between the groups, the investigators tried to quantify the effect of BMI on the bupivacaine dose requirement.
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   40 Years to 80 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients undergoing elective total knee replacement arthroplasty

Exclusion Criteria:

  • Patients with previous spine surgery, diabetic and other neuropathy, skin infection at the site of injection, allergy to bupivacaine and other common contraindications for spinal anesthesia were excluded from this study.
  • The patients with height less than 140 cm or more than 160 cm, body-mass index (BMI) less than 20 or greater than 35 were also excluded.
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01291186


Locations
Korea, Republic of
Seoul Medical Center
Seoul, Korea, Republic of, 135-740
Sponsors and Collaborators
Seoul Medical Center
Investigators
Principal Investigator: Won Ho Kim, M.D. Seoul Medical Center
  More Information

Responsible Party: Won Ho Kim M.D., Seoul Medical Center
ClinicalTrials.gov Identifier: NCT01291186     History of Changes
Other Study ID Numbers: SMC-2010-1-14
First Submitted: February 7, 2011
First Posted: February 8, 2011
Last Update Posted: August 3, 2011
Last Verified: January 2011

Keywords provided by Seoul Medical Center:
spinal anesthesia
intrathecal bupivacaine
median effective dose
height

Additional relevant MeSH terms:
Bupivacaine
Epinephrine
Racepinephrine
Epinephryl borate
Anesthetics, Local
Anesthetics
Central Nervous System Depressants
Physiological Effects of Drugs
Sensory System Agents
Peripheral Nervous System Agents
Adrenergic alpha-Agonists
Adrenergic Agonists
Adrenergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Adrenergic beta-Agonists
Bronchodilator Agents
Autonomic Agents
Anti-Asthmatic Agents
Respiratory System Agents
Mydriatics
Sympathomimetics
Vasoconstrictor Agents